Erika Finanger
Neurology with Special Qualifications in Child Neurology · Portland, ORNPI 1487709259
Payments from drug & device makers
Across 574 payments — averaging $4839.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$1.5M
- Biogen$798K
- PTC Therapeutics, Inc.$141K
- ITF Therapeutics LLC$79K
- NS Pharma, Inc.$73K
- Novartis$66K
- plus $70K from 7 others
Across 6 payments — averaging $451.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$3K
What the payments were for
- Consulting fees$131,35780%
- Speaking & faculty fees$8,0655%
- Travel & lodging$20,00112%
- Food & beverage$4,9553%
- Education$6980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 384 | $1,549,626 |
| Biogen | 39 | $798,055 |
| PTC Therapeutics, Inc. | 59 | $141,198 |
| ITF Therapeutics LLC | 11 | $79,154 |
| NS Pharma, Inc. | 11 | $73,428 |
| Novartis | 11 | $66,458 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 43 | $52,338 |
| Genentech USA, Inc. | 2 | $5,545 |
| Pfizer | 6 | $5,012 |
| Genentech, Inc. | 4 | $3,944 |
| Roche Products Limited | 1 | $1,453 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,447 |
| UCB, Inc. | 1 | $134 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Elevidys$52,447
- ZOLGENSMA$17,797
- SPINRAZA$7,820
- EVRYSDI$5,651
- Exondys 51$5,187
- Viltolarsen (NS-065/NCNP-01)$1,522
- AGAMREE$1,447
- VILTEPSO$1,326
How this compares
Too few neurology with special qualifications in child neurology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exondys-51Eteplirsen | 18 | $1,618,929 |
| EmflazaDeflazacort | 13 | $154,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sarepta Therapeutics, Inc.Exondys-51 | $1,549,626 | $1,618,92918 claims |
| PTC Therapeutics, Inc.Emflaza | $141,198 | $154,16713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Portland
- Colin RobertsPortland$837K
- Alison ChristyPortland$305K
- Ittai BushlinPortland$79K
- Yoon-Jae ChoPortland$68K
- Jenny WilsonPortland$57K
- Stephen BackPortland$3K
- Joshua KimPortland$3K
- Barry RussmanPortland$2K
- Austin LaytonPortland$906
- Jennifer HuffmanPortland$552
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.